Drug Index

Enfuvirtide

 
print

Mechanism :

Enfuvirtide interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes.


Indication :

• HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy


Contraindications :

Contraindicated in patients with known hypersensitivity to any of its components.


Dosing :

<6 years: Safety and efficacy not established.

6-16 years: 2 mg/kg twice daily up to a maximum dose of 90 mg twice daily SC.

>16 years: 90 mg SC, twice a day.


Adverse Effect :

Local injection site reactions, diarrhea, nausea, fatigue, peripheral neuropathy, insomnia, anorexia, myalgia, flu like symptoms, Guillain Barre syndrome, hypersensitivity.


Interaction :

CYP450 Metabolized Drugs: Enfuvirtide is unlikely to have significant drug interactions with concomitantly administered drugs metabolized by CYP450 enzymes.
Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.


07/18/2019 09:38:07 Enfuvirtide
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0